| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | Nov 20, 2025 | Iterum Therapeutics plc | Director | Buy | 82.5 | +6,000 | 2.55% | ✗ | $2.2K |
| Aug 8, 2025 | Aug 12, 2025 | Iterum Therapeutics plc | Director | Buy | 86.3 | +15,000 | 6.82% | ✗ | $10.9K |
| Dec 22, 2023 | Dec 27, 2023 | Iterum Therapeutics plc | Director | Buy | 91.3 | +25,000 | 28.17% | ✗ | $35K |
| Dec 18, 2023 | Dec 19, 2023 | Iterum Therapeutics plc | Director | Buy | 91.3 | +10,000 | 12.70% | ✗ | $18.4K |
| Nov 22, 2023 | Nov 27, 2023 | Iterum Therapeutics plc | Director | Buy | 91.3 | +20,000 | 34.04% | ✗ | $40.7K |
| Sep 7, 2022 | Sep 9, 2022 | Iterum Therapeutics plc | Director | Buy | 91.3 | +10,000 | 39.10% | ✗ | $22.2K |
| Jan 25, 2021 | Jan 27, 2021 | Iterum Therapeutics plc | Director | Sell | 95.0 | +46,857 | 22.37% | ✗ | $57.3K |
| Sep 4, 2018 | Sep 6, 2018 | Iterum Therapeutics plc | Chief Scientific Officer | Buy | 60.0 | +500 | 0.34% | ✗ | $5K |
| Aug 24, 2018 | Aug 28, 2018 | Iterum Therapeutics plc | Chief Scientific Officer | Buy | 68.8 | +1,000 | 0.68% | ✗ | $10K |
| May 30, 2018 | May 30, 2018 | Iterum Therapeutics plc | Chief Scientific Officer | Buy | 78.8 | +2,000 | 1.38% | ✗ | $26K |